Trump Administration Axes Key Brain Health Grants, Sparking Outcry Over Political Interference in Science
Washington D.C. – A new wave of federal grant cancellations has sent shockwaves through the scientific community, directly impacting critical brain health and Alzheimer’s disease research at Emory University and the University of Pittsburgh. These latest cancellations, totaling an estimated $15 million, are being widely interpreted as a targeted effort by the Trump administration to suppress research deemed politically unfavorable, particularly studies exploring the pervasive impacts of racism on health outcomes.
The move marks a significant escalation in what researchers and legal experts describe as a pattern of political interference in the National Institutes of Health (NIH), a scientific portfolio worth $47 billion. This pattern, they contend, undermines scientific integrity and jeopardizes vital advancements in public health.
"This kind of clear political interference – that’s not a good way to do science," stated Ann Cohen, an associate professor of psychiatry at the University of Pittsburgh, whose grant was among those abruptly terminated. Dr. Cohen, speaking in a personal capacity, expressed profound dismay, adding, "I haven’t even thought much about the why this is being done because it’s so scientifically wrong that I can’t get past that piece."
The Guardian has sought clarification from the U.S. Department of Health and Human Services, which oversees the NIH, regarding the rationale behind these cancellations but has yet to receive a response.
At least three grants across the two leading institutions were canceled. These projects were specifically designed to investigate how discrimination affects long-term brain health, with millions of dollars already invested in the ongoing work. Dr. Andrea Rosso, an associate professor of epidemiology at the University of Pittsburgh and co-lead on one of the canceled grants, echoed Dr. Cohen’s sentiments. "Those things we’re measuring are scientifically valid concepts," Rosso asserted. "Whoever was doing this saw the words they didn’t like in our grant."
The implications of these cancellations are particularly stark given the disproportionate impact of Alzheimer’s disease and dementia on certain communities. While an estimated 7.4 million Americans live with these debilitating conditions, Black Americans are twice as likely to develop Alzheimer’s or dementia, even though the majority of those affected are white.
"We don’t actually measure structural racism. We use that as a framing for why one population is at such high risk," explained Dr. Rosso, highlighting the crucial context of their research. "We can’t come up with an intervention that’s going to stop structural racism – wish we could."
These recent cancellations are not an isolated incident. In the spring of 2025, the administration controversially canceled billions of dollars in federal grants perceived to have a connection to "DEI," or diversity, equity, and inclusion initiatives. This earlier action triggered widespread lawsuits from major research institutions. A federal judge initially ruled these cancellations illegal, ordering their reinstatement. However, the Trump administration ultimately prevailed in a shadow docket ruling from the Supreme Court, which, in a 5-4 unsigned decision, permitted the termination of NIH funding totaling $783 million.
Legal experts suggest that the current round of cancellations represents a new strategy. Lawrence Gostin, a professor of global health law at Georgetown Law, believes these are "test cases" designed to be more legally defensible. "The administration, particularly [HHS] Secretary Kennedy, has followed a very clear pattern," Gostin observed. "They do something that’s clearly unlawful, they get slapped down by a federal court and then they try to cobble together a strategy that does basically the same thing but is legally defensible. I think that’s what’s going on here."
The financial and operational disruptions caused by these administrative delays have already taken a toll on researchers. In 2025, many grants, including those of Cohen and Rosso, experienced significant delays, with the administration holding up an estimated $65 million in funding for Alzheimer’s research centers nationwide. This winter, grants expected in January and February were not released until June 2026.
"At the time, we were basically trying to run the study on a shoestring, and a lot of people didn’t get paid," recounted Negar Fani, associate professor of psychiatry at Emory University. Funds were finally awarded in June of this year, only to be followed a month later by termination notices containing new, unsettling language. "We were running on fumes until we could get the second year of funds; those came in June, but the termination followed one month later," Fani added, highlighting the precarious nature of their work.
The canceled grants at the University of Pittsburgh included Dr. Rosso’s study on how Alzheimer’s disease risk is impacted in residents of historically disinvested, predominantly African American neighborhoods. Dr. Cohen’s research focused on socially driven Alzheimer’s disease risk factors, utilizing surveys, brain imaging, and blood samples to understand factors previously framed as "individual" but increasingly recognized as beyond individual control.
At Emory, Dr. Fani’s team was investigating the impact of racial discrimination on the brain’s white matter. Their sophisticated research involved surveying participants about their experiences with discrimination, employing wearable devices, conducting MRIs, and performing advanced data fusion analysis.
Dr. Jay Bhattacharya, the NIH Director, in letters described to The Guardian, stated that "the project no longer effectuates NIH’s priorities" and that "the lack of concrete, objective and measurable variables is not in alignment with NIH’s priorities." Notably, these letters frequently highlighted the inclusion of surveys, particularly self-reports of discrimination, as problematic.
"What’s most frustrating to me about all of this is this assertion that – in the most basic way – the assertion that our outcomes are not measurable or scientific," Dr. Cohen passionately argued. "[It] demonstrates a lack of understanding of our outcomes versus our exposures – that’s epidemiology 101."
Dr. Fani echoed this sentiment, pointing out the broader implications of dismissing self-reported data. "It was saying that self-reported measures are not scientifically valid, and as a scientist that would rule out a large portion of our entire field," she explained. "We ask people about their trauma, and symptoms, and depression, to lifestyle, to their reports about alcohol and substance abuse, their reports about physical pain and medication usage. Those perceptions get under the skin, into the brain, and affect in real ways health."
The scientific community now faces a profound challenge as it grapples with these politically motivated cancellations, raising serious questions about the future of independent research and the pursuit of crucial health insights, particularly those addressing systemic inequalities.
